Eli Lilly and Stock LLY · Forecast & Analysis
Heads-up: USD Michigan Consumer Sentiment is due in 21 h (high impact). The outlook can shift noticeably around it.
Eli Lilly and Company (LLY) reads bullish on news flow: a Phase 3 win for oral GLP-1 Foundayo in sleep apnea, strong ObesityWeek data and a new consumer channel. With no chart signals, the view rests on fundamentals, tempered by Mounjaro lawsuits.
News situation · 20 items / 30 D
17 of 20 straight from the issuer or regulator
Outlook for Eli Lilly and Company
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
No price statement: there is no price data for this asset. Based on 20 news items.
What drives it
- Foundayo, Lilly's oral GLP-1, met its Phase 3 goal in sleep apnea, with an FDA filing planned by end of 2026
- ObesityWeek presentations show strong weight-loss and sleep-apnea results for EloraTZP and retatrutide
- Zepbound and Foundayo gain a direct-to-consumer channel via Hims & Hers, with self-pay pricing from $149 a month
- Retatrutide Phase 3 trials showed large knee-pain reductions in osteoarthritis patients with obesity
What argues against it
- Lawsuits allege NAION eye damage from Mounjaro, a safety challenge to a flagship GLP-1 medicine
- The pipeline data come from investigational drugs that cannot yet be sold, so revenue stays distant
- Financial terms of the Hims & Hers deal and the small Calytrix Bio acquisition were not quantified
What would change the picture
- Whether Eli Lilly files the FDA submission for Foundayo in sleep apnea by the end of 2026
- Any expansion of the NAION lawsuits or regulatory scrutiny of Mounjaro's safety
- US retail sales and jobs data due shortly set only the macro backdrop for large American stocks
Coming up
- US: Michigan Consumer Sentiment · expected 51.0, previous 51.0
- US: CB Consumer Confidence Index · expected 91.5, previous 91.7
- US: PCE price index, Jobless claims, GDP · expected 3.6%, previous 3.6%
Economic data for LLY
Full calendarRecently released
- TodayUSDPhiladelphia Fed Manufacturing Index●●●Forecast 32.2Previous 20.9
- TodayUSDInitial Jobless Claims●●●
- November 18, 2026USDEIA Crude Oil Stocks Change●●●Actual 3.380MForecast -0.309MPrevious 4.657M
- November 17, 2026USDCore Retail Sales m/m●●●Actual 0.6%Forecast 0.7%Previous 1.1%
- November 17, 2026USDRetail Sales m/m●●●Actual 0.2%Forecast 0.3%Previous 0.8%
Coming up
- TomorrowUSDMichigan Consumer Sentiment●●●Forecast 51.0Previous 51.0in 21h
- November 24, 2026USDCB Consumer Confidence Index●●●Forecast 91.5Previous 91.7in 4 days
- November 25, 2026USDPCE Price Index y/y●●●Forecast 3.6%Previous 3.6%in 5 days
- November 25, 2026USDPCE Price Index m/m●●●Forecast 0.4%Previous 0.5%in 5 days
- November 25, 2026USDInitial Jobless Claims●●●in 5 days
- November 25, 2026USDCore PCE Price Index y/y●●●Forecast 3.1%Previous 3.1%in 5 days
- November 25, 2026USDCore PCE Price Index m/m●●●Forecast 0.3%Previous 0.3%in 5 days
- November 25, 2026USDGDP Sales q/q●●●Forecast 1.7%Previous 1.7%in 5 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about LLY
Frequently asked questions about Eli Lilly and Company
What is the most important recent development for LLY?
Foundayo, the oral GLP-1 pill, met its primary endpoint in the Phase 3 ATTAIN-OSA trial, cutting sleep-apnea severity and body weight, with an FDA submission for that new use planned by end of 2026. The result was largely anticipated, but it would extend an already approved pill into a huge sleep-apnea market.
How serious are the Mounjaro lawsuits?
A law firm has filed multiple suits alleging eye-nerve damage (NAION) after Mounjaro use. That challenges the safety profile of a flagship GLP-1 medicine and can weigh on sentiment, but the filings are early, and any liability cost or regulatory consequence is not yet known.
What could change the bullish picture?
The clearest markers are the planned FDA filing for Foundayo in sleep apnea by end of 2026, any expansion of the NAION litigation, and, further out, approvals for the still-investigational retatrutide and EloraTZP. Conference data alone, however strong, do not yet add revenue.
📝 Overview Generated automatically
LLY has been the subject of 73 signals across 73 articles in the last 365 days. Sentiment skews Bullish (45%).
Breakdown: 33 bullish, 7 bearish, 33 neutral.
Most-cited catalysts: Supreme Court denies appeal on $194 million Medicaid penalty (1×), Immediate earnings charge in upcoming quarter (1×), Validation of oral GLP-1 category by EMA (1×). Most-cited risk factors: Lilly's strong cash position may mitigate market reaction (1×), Ruling was expected and priced in (1×), Novo's oral Wegovy may establish strong brand loyalty before Lilly's launch (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.